Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2019

View Archived Issues

Killer T cells protected by membrane lipid order and charge

Enterovirus contributes to islet autoimmunity

CARsgen Therapeutics receives IND clearance for AB-011 in China

Scohia Pharma initiates phase I study of SCO-267

IND for HLX-10 plus HLX-07 antibody combination therapy approved in China

FDA clears IND application for first-in-human study of CPT-31

Intrathecal AVXS-301 shows promise in preclinical models of ALS

Implicit Bioscience presents phase I data for IC-14 in motor neuron disease

Anti-BCMA CAR-T candidate C-CAR088 shows early clinical efficacy

Pfizer gives details on the discovery of novel noncovalent modulator of hemoglobin

First-in-human study of LOXO-305 confirms it as a potent anti-BTK agent for B-cell malignancies

The anti-CD33/CD3 BiTE AMG-673 shows promise as treatment for relapsed/refractory AML

GenSight reports on REALITY registry study in support of Lumevoq

Three phase III trials of tralokinumab in atopic dermatitis meet endpoints

Xeris reports in-clinic stage data from phase II trial of RTU glucagon

Constellation Pharmaceuticals patents EZH2 inhibitors

Primmune Therapeutics discloses new TLR7 agonists

VenatoRx Pharmaceuticals patent details bacterial PBP3 inhibitors

Alligator initiates first-in-human study of 4-1BB antibody ATOR-1017

University of Texas System identifies KRAS-targeting compounds

hSTING agonists described in Incyte patent

Iterum reports topline data from phase III trial of sulopenem in cIAI

EicOsis initiates phase I trial of sEH inhibitor EC-5026 for pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...